A Novel Diagnostic Biomarker, PZP, for Detecting Colorectal Cancer in Type 2 Diabetes Mellitus Patients Identified by Serum-Based Mass Spectrometry
Background: Growing evidence has confirmed that populations with type 2 diabetes mellitus (T2DM) have an increasing risk of developing colorectal cancer (CRC). Thus, convenient and effective screening strategies for CRC should be developed for the T2DM population to increase the detection rate of CR...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-11-01
|
| Series: | Frontiers in Molecular Biosciences |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmolb.2021.736272/full |
| _version_ | 1818682479164260352 |
|---|---|
| author | Jiayue Yang Weigang Fang Wenjun Wu Zhen Tian Rong Gao Lu Yu Dayang Chen Xiaohua Weng Shengwei Zhu Cheng Yang |
| author_facet | Jiayue Yang Weigang Fang Wenjun Wu Zhen Tian Rong Gao Lu Yu Dayang Chen Xiaohua Weng Shengwei Zhu Cheng Yang |
| author_sort | Jiayue Yang |
| collection | DOAJ |
| description | Background: Growing evidence has confirmed that populations with type 2 diabetes mellitus (T2DM) have an increasing risk of developing colorectal cancer (CRC). Thus, convenient and effective screening strategies for CRC should be developed for the T2DM population to increase the detection rate of CRC.Methods: Twenty serum samples extracted from five healthy participants, five T2DM patients, five CRC patients and five T2DM patients with CRC (T2DM + CRC) were submitted to data-independent acquisition mass spectrometry (DIA-MS) analysis to discover unique differentially altered proteins (DAPs) for CRC in patients with T2DM. Then, the diagnostic value of pregnancy zone protein (PZP) was validated by ELISA analysis in the validated cohort.Results: Based on DIA-MS analysis, we found eight unique proteins specific to T2DM patients with CRC. Among these proteins, four proteins showed different expression between the T2DM + CRC and T2DM groups, and PZP exhibited the largest difference. Next, the diagnostic value of serum PZP was validated by ELISA analysis with an AUC of 0.713. Moreover, the combination of PZP, CA199 and CEA exhibited encouraging diagnostic value, and the AUC reached 0.916.Conclusion: Overall, our current research implied that PZP could be regarded as a newfound serum biomarker for CRC medical diagnosis in T2DM patients. |
| first_indexed | 2024-12-17T10:19:30Z |
| format | Article |
| id | doaj.art-7b7d3051e1494d88a55880349c2c8e84 |
| institution | Directory Open Access Journal |
| issn | 2296-889X |
| language | English |
| last_indexed | 2024-12-17T10:19:30Z |
| publishDate | 2021-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Molecular Biosciences |
| spelling | doaj.art-7b7d3051e1494d88a55880349c2c8e842022-12-21T21:52:49ZengFrontiers Media S.A.Frontiers in Molecular Biosciences2296-889X2021-11-01810.3389/fmolb.2021.736272736272A Novel Diagnostic Biomarker, PZP, for Detecting Colorectal Cancer in Type 2 Diabetes Mellitus Patients Identified by Serum-Based Mass SpectrometryJiayue Yang0Weigang Fang1Wenjun Wu2Zhen Tian3Rong Gao4Lu Yu5Dayang Chen6Xiaohua Weng7Shengwei Zhu8Cheng Yang9Department of Endocrinology, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi, ChinaDepartment of Gastroenterology, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi, ChinaDepartment of Endocrinology, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi, ChinaDepartment of Clinical Laboratory, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi, ChinaDepartment of Clinical Laboratory, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi, ChinaDepartment of Endocrinology, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi, ChinaDepartment of Gastroenterology, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi, ChinaDepartment of Endocrinology, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi, ChinaDepartment of Endocrinology, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi, ChinaDepartment of Gastroenterology, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi, ChinaBackground: Growing evidence has confirmed that populations with type 2 diabetes mellitus (T2DM) have an increasing risk of developing colorectal cancer (CRC). Thus, convenient and effective screening strategies for CRC should be developed for the T2DM population to increase the detection rate of CRC.Methods: Twenty serum samples extracted from five healthy participants, five T2DM patients, five CRC patients and five T2DM patients with CRC (T2DM + CRC) were submitted to data-independent acquisition mass spectrometry (DIA-MS) analysis to discover unique differentially altered proteins (DAPs) for CRC in patients with T2DM. Then, the diagnostic value of pregnancy zone protein (PZP) was validated by ELISA analysis in the validated cohort.Results: Based on DIA-MS analysis, we found eight unique proteins specific to T2DM patients with CRC. Among these proteins, four proteins showed different expression between the T2DM + CRC and T2DM groups, and PZP exhibited the largest difference. Next, the diagnostic value of serum PZP was validated by ELISA analysis with an AUC of 0.713. Moreover, the combination of PZP, CA199 and CEA exhibited encouraging diagnostic value, and the AUC reached 0.916.Conclusion: Overall, our current research implied that PZP could be regarded as a newfound serum biomarker for CRC medical diagnosis in T2DM patients.https://www.frontiersin.org/articles/10.3389/fmolb.2021.736272/fullbiomarkercolorectal cancertype 2 diabetes mellitusmass spectrumPZP |
| spellingShingle | Jiayue Yang Weigang Fang Wenjun Wu Zhen Tian Rong Gao Lu Yu Dayang Chen Xiaohua Weng Shengwei Zhu Cheng Yang A Novel Diagnostic Biomarker, PZP, for Detecting Colorectal Cancer in Type 2 Diabetes Mellitus Patients Identified by Serum-Based Mass Spectrometry Frontiers in Molecular Biosciences biomarker colorectal cancer type 2 diabetes mellitus mass spectrum PZP |
| title | A Novel Diagnostic Biomarker, PZP, for Detecting Colorectal Cancer in Type 2 Diabetes Mellitus Patients Identified by Serum-Based Mass Spectrometry |
| title_full | A Novel Diagnostic Biomarker, PZP, for Detecting Colorectal Cancer in Type 2 Diabetes Mellitus Patients Identified by Serum-Based Mass Spectrometry |
| title_fullStr | A Novel Diagnostic Biomarker, PZP, for Detecting Colorectal Cancer in Type 2 Diabetes Mellitus Patients Identified by Serum-Based Mass Spectrometry |
| title_full_unstemmed | A Novel Diagnostic Biomarker, PZP, for Detecting Colorectal Cancer in Type 2 Diabetes Mellitus Patients Identified by Serum-Based Mass Spectrometry |
| title_short | A Novel Diagnostic Biomarker, PZP, for Detecting Colorectal Cancer in Type 2 Diabetes Mellitus Patients Identified by Serum-Based Mass Spectrometry |
| title_sort | novel diagnostic biomarker pzp for detecting colorectal cancer in type 2 diabetes mellitus patients identified by serum based mass spectrometry |
| topic | biomarker colorectal cancer type 2 diabetes mellitus mass spectrum PZP |
| url | https://www.frontiersin.org/articles/10.3389/fmolb.2021.736272/full |
| work_keys_str_mv | AT jiayueyang anoveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry AT weigangfang anoveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry AT wenjunwu anoveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry AT zhentian anoveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry AT ronggao anoveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry AT luyu anoveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry AT dayangchen anoveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry AT xiaohuaweng anoveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry AT shengweizhu anoveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry AT chengyang anoveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry AT jiayueyang noveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry AT weigangfang noveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry AT wenjunwu noveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry AT zhentian noveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry AT ronggao noveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry AT luyu noveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry AT dayangchen noveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry AT xiaohuaweng noveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry AT shengweizhu noveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry AT chengyang noveldiagnosticbiomarkerpzpfordetectingcolorectalcancerintype2diabetesmellituspatientsidentifiedbyserumbasedmassspectrometry |